In a study reported by Sarnaik et al., lifileucel was administered to patients with unresectable or metastatic melanoma, previously progressed through anti-PD-1 blockade (and targeted treatment if they had BRAF V600 mutation-positive disease) [77]. This evidence concerns the gene BRAF and metastatic melanoma.